drugset / Trial / NCT00430950
Combination of Olmesartan and Hydrochlorothiazide in Essential Hypertension
Phase 3
Completed
1011 enrolled
Daiichi Sankyo
Daiichi Sankyo Europe, GmbH, a Daiichi Sankyo Company · collab
RandomizedParallel-groupDouble-blindTreatment
Summary
The study will evaluate the blood pressure lowering effects of two different dosages of the combination of olmesartan and hydrochlorothiazide in patients with moderate or severe high blood pressure.
Timeline
- Start
- 2007-02
- Primary completion
- 2008-05
- Completion
- 2008-10
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Hydrochlorothiazide | Unknown | 25 mg | — |
| Subject | Olmesartan medoxomil | Unknown | 20 mg | — |
| Subject | Olmesartan medoxomil | Unknown | 40 mg | — |